Spironolactone reduces mortality in heart failure

Kaplan-Meier analysis of survival among 1663 patients with advanced heart failure in the RALES trial shows that spironolactone reduces mortality by 30 percent (35 versus 46 percent for placebo, p<0.001).

Data from: Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.

Graphic 76232 Version 3.0